Evidence map›Paper›PMID 40696381›Full record

ArticleBreast cancer research : BCR2025

Retinoic acid-induced 2 deficiency impairs genomic stability in breast cancer.

Lena Boettcher, Sarah Greimeier, Kerstin Borgmann, Shabbir S Mughal, Bernhard Ellinger, Kai Bartkowiak, Bernd Zobiak, Antonio V Failla, Pascal Steffen, Ellen Claus and 13 more

Abstract read
In one paragraph

Article in Breast cancer research : BCR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Lena BoettcherInstitute of Tumour Biology, University Medical Centre Hamburg-Eppendorf, 20246, Hamburg, Germany.
Sarah GreimeierInstitute of Tumour Biology, University Medical Centre Hamburg-Eppendorf, 20246, Hamburg, Germany.
Kerstin BorgmannDepartment of Radiotherapy and Radiooncology, University Medical Centre Hamburg-Eppendorf, 20246, Hamburg, Germany.
Shabbir S MughalDivision of Applied Bioinformatics (G330), German Cancer Research Center (DKFZ), Heidelberg, Germany.
Bernhard EllingerDepartment Screening Port, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, 22525, Hamburg, Germany.
Kai BartkowiakInstitute of Tumour Biology, University Medical Centre Hamburg-Eppendorf, 20246, Hamburg, Germany.
Bernd ZobiakUKE Microscopy Imaging Facility, University Medical Centre Hamburg-Eppendorf, 20246, Hamburg, Germany.
Antonio V FaillaUKE Microscopy Imaging Facility, University Medical Centre Hamburg-Eppendorf, 20246, Hamburg, Germany.
Pascal SteffenSection Mass Spectrometric Proteomics, University Medical Centre Hamburg- Eppendorf, 20246, Hamburg, Germany.
Ellen ClausInstitute of Tumour Biology, University Medical Centre Hamburg-Eppendorf, 20246, Hamburg, Germany.
Katharina BeslerInstitute of Tumour Biology, University Medical Centre Hamburg-Eppendorf, 20246, Hamburg, Germany.
Christopher BuccitelliEuropean Molecular Biology Laboratory (EMBL), Genome Biology Unit, 69117, Heidelberg, Germany.
Violetta SchaafRuprecht-Karls-Universität Heidelberg, 69117, Heidelberg, Germany.
Ann-Kathrin OzgaInstitute of Medical Biometry and Epidemiology, University Medical Centre Hamburg-Eppendorf, 20246, Hamburg, Germany.
Simona ParrettaInstitute of Tumour Biology, University Medical Centre Hamburg-Eppendorf, 20246, Hamburg, Germany.
Svenja SchneegansInstitute of Tumour Biology, University Medical Centre Hamburg-Eppendorf, 20246, Hamburg, Germany.
Wael Y MansourDepartment of Radiotherapy and Radiooncology, University Medical Centre Hamburg-Eppendorf, 20246, Hamburg, Germany.
Jan O KorbelEuropean Molecular Biology Laboratory (EMBL), Genome Biology Unit, 69117, Heidelberg, Germany.
Hartmut SchlueterSection Mass Spectrometric Proteomics, University Medical Centre Hamburg- Eppendorf, 20246, Hamburg, Germany.
Benedikt BrorsDivision of Applied Bioinformatics (G330), German Cancer Research Center (DKFZ), Heidelberg, Germany.
Klaus PantelInstitute of Tumour Biology, University Medical Centre Hamburg-Eppendorf, 20246, Hamburg, Germany.
Harriet WikmanInstitute of Tumour Biology, University Medical Centre Hamburg-Eppendorf, 20246, Hamburg, Germany.
Stefan WernerInstitute of Tumour Biology, University Medical Centre Hamburg-Eppendorf, 20246, Hamburg, Germany. st.werner@uke.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGenome instability is a fundamental feature and hallmark of cancer, associated with aggressiveness, drug resistance and poor prognosis. RAI2 was initially identified as a novel metastasis suppressor protein specifically associated with the presence of disseminated tumour cells in the bone marrow of breast cancer patients, but its molecular function is largely unknown.

methodsWe analysed the consequences of RAI2 depletion on gene expression and genomic stability in luminal breast cancer cell lines, performed cytotoxicity profiling using a library of pharmacologically active compounds, and characterized a potential function of the RAI2 protein in the DNA damage response. We performed in silico validation in different breast cancer datasets.

resultsAnalysis of clinical samples revealed that in primary breast tumours, low RAI2 gene expression is significantly associated with genomically unstable tumours and poor prognosis. RAI2 depletion in breast cancer cell lines resulted in loss of mitotic fidelity characterized by prolonged mitosis with increased chromosome segregation errors and micronuclei formation. Drug screening revealed increased sensitivity of RAI2-depleted breast cancer cells to topoisomerase I and Aurora A inhibitors. We also found that genotoxic stress induces the RAI2 protein, which has an affinity for and colocalises with poly-(ADP-ribose). We validated the association of RAI2 gene expression with DNA repair capacity in clinical samples.

conclusionsOur findings support, for the first time, a functional role of RAI2 in the maintenance of genomic stability. Understanding the underlying the molecular mechanism could help to improve patient diagnosis and treatment.

Indexed as

Alcohol OxidoreductasesBreast NeoplasmsGenomic InstabilityCell Line, TumorDNA DamageDNA RepairFemaleGene Expression Regulation, NeoplasticHumansPrognosisRibonucleoside Diphosphate ReductaseAlcohol OxidoreductasesRibonucleoside Diphosphate Reductaseribonucleotide reductase M2Breast cancerDNA damage responseGenomic instabilitypoly-(ADP-ribose)Premature mitotic entry

Identifiers

PMID40696381
PMCPMC12285165

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.